Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Prostate cancer
      • Bladder cancer
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • Media
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
    • Our annual accounts
    • Pelican Cancer Foundation – What next?
    • Support Us
    • Job opportunities
    • Partners
  • Workshops
    • TIPTOP
      • Workshops
      • TIPTOP – online resources
    • IMPACT
      • Workshops
      • IMPACT – online resources
      • IMPACT news
      • IMPACT partners and sponsors
    • SPECC
      • Workshops
      • Online resources
      • SPECC Partners and Sponsors
      • SPECC News
    • LOREC
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Prostate Cancer Research
      • Focal therapy and HIFU research
      • MRI research for prostate cancer
      • Prostate cancer colloquiums
      • FORECAST
      • Trachtomap
      • Papers of interest
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Bladder cancer research
      • PELT
      • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Jay’s story (bladder cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Prostate cancer
      • Our prostate cancer team
      • Prostate cancer treatment options
      • Pelican’s position
    • Bladder cancer
      • Blue light cystoscopy
      • Bladder cancer – useful contacts
    • Pseudomyxoma peritonei
    • Kidney cancer
      • Our kidney cancer team
      • Kidney cancer – useful contacts
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
        • How your donations are spent
    • Events and Challenges
    • Leaving a Legacy
    • Fundraising
      • Our fundraisers
      • Fundraising pack
      • Fundraising opportunities
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Charity of the Year partnerships
    • Pelican Film Society
  • Online Shop
  • Events
  • Contact us

January 2021 – COVID-19 update from Pelican Cancer Foundation

January 20, 2021 by pelicanadmin

The team have settled in to working from home now and are focusing on moving the charity forwards. We remain steadfast in our commitment and mission of driving innovation and development in bowel cancer, focusing particularly on surgical treatment.

The Trustees continue to meet regularly to review the current situation and the team are working hard to support this. When the situation locally and nationally allows it, we look to resume our education and training activities both remotely and using more traditional delivery methods where possible. We are acutely aware of the current challenges facing staff across the NHS and how extremely hard they are working to treat all patients who need attention.

Our office is still housing staff from Basingstoke hospital, in order to free up space for clinical services in the hospital.

As the year progresses, we are hopeful that the vaccination programme and its rollout will gradually improve the situation for all. We look forward to delivering our excellent education programmes as soon as it is possible to do so.

Filed Under: Latest news, News, Slider

Pelican IMPACT completes a successful two-year run

February 7, 2020 by pelicanadmin

Pelican IMPACT has now drawn to a close after two years on the road. Our workshop in Kent on the 17th January was the grand finale in what has been a broad-reaching and highly successful programme delivered throughout the UK and Ireland.

Professor Brendan Moran commented: “Spearheaded by Pelican Cancer Foundation and the current President of the Association of Coloproctology of Great Britain and Ireland, Nicola Fearnhead, in conjunction with Professor Jim Hill, ACPGBI President 2017-2018 – and myself as immediate past-president in 2018-2019, IMPACT combined the experience of Pelican Cancer Foundation in MDT Course development and delivery with the clinical leadership of ACPGBI.

We are particularly grateful to our two main donors, The Lady Yuen Peng McNeice Charitable Foundation and the ACPGBI for the enormous financial support which made this venture possible. This initiative will improve outcomes for many of our most ill patients and will help integrate the crucial role of palliative care in complex cancer pathways. More patients will be cured and best care delivered to all. Thank you Pelican Cancer Foundation, ACPGBI, and all participants!”.

Filed Under: Latest news

Pelican’s pioneering prostate cancer programme launched in Manchester

March 5, 2019 by pelicanadmin

Urology teams in Manchester are at the forefront of a national development programme to improve the diagnosis and treatment of prostate cancer and are being helped by Pelican Cancer Foundation.

The first “Transformation in the Prostate Cancer Pathway: Teamwork for Patients” (TIPTOP) workshop was held in Manchester in February 2019.

After supporting prostate cancer research for the last 16 years, the Pelican team led by Consultant Urological Surgeon Mr Satish Maddineni presented the latest findings and recommendations around the UK to help patients achieve a timely and accurate diagnosis and further treatment.

The day-long presentations for regional prostate cancer teams (MDTs) – including urologists, radiologists, clinical nurse specialists, pathologists, oncologists,radiographers and cancer managers  – were designed to raise awareness of how the diagnosis of prostate cancer is rapidly changing. For example, the introduction of MRI scans before taking a biopsy with the subsequent reduction in the number of patients requiring biopsies and therefore improving the accuracy of the biopsies themselves. The programme also outlined how patients should get their diagnosis much faster – ideally within 14 days; and the increase in treatment options.

The inaugural TIPTOP workshop, held at The LifeCentre in Sale, considered the best way forward, for both logistics and clinical developments. In addition to the presentations from medical experts and discussions, the MDT members from 12 hospitals in the Manchester area had the opportunity to network, meet colleagues and representatives from the Greater Manchester Cancer Alliance including Professor David Shackley, Medical Director for GM Cancer.

One of the delegates from The Christie Hospital commented afterwards: “Everybody went away enthused and I look forward to progress being made in the North West.”

Another prostate cancer specialist said: “It was extremely interesting. As a result, I will work with urology experts and radiologists to improve access to MRI scanning and improve any time constraints.”

Prostate cancer survival is improving and has tripled in the last 40 years, however it remains the second most common cause of male cancer death with in the UK, with more than 47,200 new cases in 2015.

Mr Maddineni, consultant urologist at Salford Royal, said: “Pelican is very pleased and proud to bring the TIPTOP programme to prostate cancer teams around the country. It aims to raise awareness and give an improved understanding of the optimal diagnostic pathway for prostate cancer which they can then incorporate into their own practices.”

“The recent developments in imaging and prostate cancer diagnostic techniques, coupled with the arrival of new technologies that can destroy areas of cancer in the prostate, have enabled many men to enjoy a good quality of life after treatment.”

Pelican’s Chief Executive Sarah Crane said: “Pelican Cancer Foundation’s groundbreaking new programme will work with cancer specialists to adopt changes in the diagnosis of prostate cancer, with the aim of reducing the number of men who are diagnosed every year, and improving treatment for those who are.

“Our free workshops in Britain and Ireland are designed to help these specialist cancer teams treat patients for the best possible outcome. The programme will not only improve clinical confidence in prostate cancer care, it could also make long-term savings for the NHS.”

Filed Under: Latest news, Uncategorized

Pelican partners with MRSL as their charity of the year

October 2, 2018 by pelicanadmin

We are really excited to be partnering with medical insurance company MRSL Enterprise as their charity of the year!

Founded by a former Head of Operations of the NHS Litigation Authority and a PhD Engineer, MRSL focusses on insurances for medical risks. The core of their business is to work with medical businesses – surgeons, doctors, dentists and ancillary healthcare to understand their risks, and to develop products and accurate pricing to completely indemnify and insure these businesses.

MRSL Enterprise is also committed to obtaining fair insurance for those who wish to travel with medical conditions, including cancer.  If you do speak to MRSL Enterprise – please mention that you found them through Pelican Cancer Foundation. MRSL Enterprise will then make a donation to Pelican.

MRSL’s Chris Cloke Browne visited the Pelican offices and met with our community fundraiser Tim Lockwood to discuss future event plans with us.

MRSL Enterprise plans to:

  • Promote Pelican’s work and values
  • Make relevant corporate donations to the charity throughout the year as situations arise
  • Assist in the work of Pelican in a non-financial way, using practical and specialist help

We are hugely looking forward to working with MRSL over the next 12 months.

 

Filed Under: Latest news, Uncategorized

Pelican Cancer FoundationFollow

Pelican Cancer Foundation
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
22 Dec

We would like to wish you all a very Merry Christmas and a peaceful New Year - especially to all the wonderful key workers, who will be working throughout. 🎄🥂🎁

Reply on Twitter 1341352794255593477Retweet on Twitter 1341352794255593477Like on Twitter 13413527942555934771Twitter 1341352794255593477
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
7 Dec

👏

Reply on Twitter 1335864743752589312Retweet on Twitter 1335864743752589312Like on Twitter 13358647437525893122Twitter 1335864743752589312
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
5 Dec

Let loved ones know that you are thinking of them over the festive period and send a handwritten Christmas card. Order your Christmas cards from us at http://www.pelicancancer.org/shop. 🎄(Royal Mail’s latest recommended posting dates are 18th Dec (2nd Class) and 21st Dec (1st Class). 🎄

Reply on Twitter 1335126762079068160Retweet on Twitter 1335126762079068160Like on Twitter 1335126762079068160Twitter 1335126762079068160
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2021 · Outreach Pro Theme on Genesis Framework · WordPress · Log in